Thus, we focused on demonstrating the antifibrotic effect of HGF-based ADSC therapy and establishing the cellular and molecular mechanism by using an in vitro model of activated HSCs, the key player of liver fibrogenesis, and an in vivo model of CCl4-induced liver fibrosis in diabetic mice. This evidence concerns the gene HGF and Hepatic fibrosis.